Caprock Group LLC Takes $3.10 Million Position in AstraZeneca PLC $AZN

Caprock Group LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 38,595 shares of the company’s stock, valued at approximately $3,103,000.

A number of other institutional investors have also recently bought and sold shares of the business. Chapin Davis Inc. lifted its position in shares of AstraZeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after buying an additional 120 shares during the last quarter. CoreCap Advisors LLC raised its stake in AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after acquiring an additional 125 shares during the period. Highline Wealth Partners LLC raised its stake in AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after acquiring an additional 129 shares during the period. Traub Capital Management LLC lifted its holdings in AstraZeneca by 3.3% during the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock valued at $316,000 after purchasing an additional 130 shares during the last quarter. Finally, Aaron Wealth Advisors LLC boosted its position in AstraZeneca by 0.6% during the third quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after purchasing an additional 136 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Citigroup assumed coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Barclays restated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Finally, HSBC reissued a “buy” rating and set a $108.00 price target on shares of AstraZeneca in a report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Up 0.2%

NASDAQ AZN opened at $205.23 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The company has a market cap of $318.30 billion, a price-to-earnings ratio of 68.18, a PEG ratio of 1.59 and a beta of 0.34. The company has a 50 day moving average of $110.42 and a 200-day moving average of $91.89. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $205.86.

AstraZeneca Dividend Announcement

The business also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be given a dividend of $1.595 per share. This represents a dividend yield of 165.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s dividend payout ratio is presently 34.77%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.